Owen Mumford Sdn Bhd, subsidiary of UK-based medical device manufacturer Owen Mumford, has announced a partnership with Duopharma Biotech Berhad subsidiary Duopharma Marketing Sdn Bhd to distribute its diabetes and eye care products in Malaysia and Brunei.
Shutterstock
Owen Mumford’s insulin pen needles, capillary blood sampling lancets, and eye drop dispensers will be issued to retail outlets, government, private healthcare and other patient care facilities to provide better access and support those living with diabetes in the region. The partnership was announced in a ceremony attended by VIPs including YBhg Datuk Wira Arham Abdul Rahman, chief executive officer, Malaysian Investment Development Authority (MIDA) and British High Commissioner to Malaysia, Ailsa Terry.
The number of people living with diabetes in Malaysia is growing each year and is expected to hit 7million in 2025. As these numbers continue to rise, it is essential for those living with the disease to have access to safe and practical solutions to manage it effectively. Since it began operations in 1952, Owen Mumford has been committed to improving the wellbeing of those living with diabetes and has created some of the world’s first technology for diabetes management, including the first automatic lancing device for easier blood sampling, the first automatic insulin pen for more practical drug delivery, and many other innovative solutions that have helped improve the lives of the millions of people living with the disease across the world.
Owen Mumford’s partnership with Duopharma Biotech supports both company’s efforts to provide more options for the millions of people living with diabetes in Malaysia and support their treatment journeys with care based on their individual needs.
“Since Owen Mumford Malaysia began operations in 2015, we have focused on elevating healthcare through engagement with patients and healthcare professionals and tailoring medical devices to meet their needs, besides conducting ongoing education to ensure the correct usage of devices for optimal healthcare outcomes,” said Shirley Loh, regional managing director at Owen Mumford Sdn Bhd. “We are committed to delivering innovative, high-quality products and have launched initiatives such as including pen needles in complimentary bespoke starter kits at local government hospitals and provided vouchers to support patients in the B40 demographic. With nearly RM100 million invested into our manufacturing facilities, operations and programmes in Malaysia since 2015, we aspire to continue serving as a source of advanced medical solutions in the country.”